MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Odonate Therapeutics, Inc.(NASDAQ:ODT) i
Organization & Developments: Odonate
Parents
Odonate Therapeutics, Inc.(NASDAQ:ODT) i
Children
2019: It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer.
2021: Odonate abandons breast cancer chemo drug, closes its doors
2021: Revisiting Odonate Therapeutics
2021: Tesetaxel is an oral chemotherapy drug, which Odonate Therapeutics licensed from Daiichi Sankyo in 2013
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.
Jumps
*Key People: Odonate
Finance & Acquisitions: Odonate